Evaluation of cardiac ejection fraction and fractional shortening following oral administration of cisapride in dogs

Document Type : Full Research Paper

Authors

1 Department of Animal Science, Payam Noor University, B.O.Box: 19395-3697, Tehran, Iran.

2 Doctor of Veterinary Medicine, Jahad – Agriculture organization of Hamedan.

Abstract

Cispride drug as a procinetic drug in digestive system, causes prolongation of the QT interval by electrophysiologic changes in the ion channel that is responsible for the rapid component of the delayed rectifier current for potassium (IKr). This drug is metabolized by cytochrome P450. However, serious cardiac arrhythmias have been reported in patients taking cisapride like ventricular tachycardia and hypokinetic heart. The goal of this issue is to measure the ventricular size by evaluating of ejection fraction and fractional shortening following oral administration of cisapride.In this appraisal, six domestic dogs were randomly selected. Then all of them were issued on echocardiographic changes in two times as before administration and after administration of 1 mg/kg cisapride for three times day. Two- dimensional B-mode and M-mode pictures were analysed.The results confirmed that by oral administration of cisapride ventricular function became impaired and the Frank-Starling law of the heart was note operative. The side effects were reduction of heart rate, declining of ejection fraction and fractional shortening which resulted Decreased cardiac contractility heart.

Keywords

References


1.Avram,B.,F.Arjen.,D.Tine andV.Yvan.2000. Effects of Cisapride on Corrected QT Interval,Heart Rate, and Rhythm in Infants Undergoing Polysomnography. Pediatrics106 (6): 85.
2.Ahmed, S.R.1995. Cisapride and torsades de pointes.The Lancet. 345-508.
3.AlWabel,N.A.,Strauch.,S.M.Keene.,B.W.Nakayama.,N.Hamlin.2002.Electrocardiographic and Hemodynamic Effects of Cisapride Alone and Combined with Erythromycin in Anesthetized Dogs. Cardiovascular Toxicology:195- 207.
4.Diego,J.,M.D.Belardinelli.,L.Antzelevitch,C.2003.Cisapride-Induced‌Transmural Dispersion of Repolarization and Torsade de Pointes in the Canine Left Ventricular Wedge Preparation During Epicardial Stimulation. Circulation:108.1027.
5.Dowling,P.M.1995.Prokinetic drugs: metoclopramide and cisapride. Canad.Vet.J: 115-116.
6.Hondeghem,L.M and D.L.Synders.1990.Class III antiarrhythmic drugs have a lot of potential but a long way to go: reduced efffectiveness and dangers of reverse use – dependence. Circulation: 686-690.
7.Kuroda,T.,y.Yoshihara.,H.Nakamura.1992.Effects of cisapride on gastrointestinal motor activity and gastric emptying of disopyramide. J. Pharmaco-Dyn:395-402.
8.Libby,P.,R.O.Bonow.,D.L. Mann.,D.P. Zipes.2008.Braunwald's Heart Disease, Eighth Ed, Philadelphia, Saunders Elsevier:149-974.
9.Liu,S.,R.B., Melchert.,R.H and Kennedy.1997. Inhibition of L-type Ca 2+ channel current in rat ventricular mycoytes by terfenadine. Circ Res: 202-210.
10.Nolan,E.R.,M.R.Feng.,J.R. Koup.,J. Liu.,D. Turluck.,Y. Zhang and et al.2006. A novel predictive pharmacokinetic/pharmacodynamic model of repolarization prolongation derived from the effects of terfenadine, cisapride and E-4031 in the conscious chronic av node-ablated, His bundle-paced dog. J Pharmacol Toxicol Methods:1-10.
11. O'Rourke, R.A. Walsh and V. Fuster.2009. Hurst's The Heart.12 ed. pp.90-216,in: canada.. McGraw-Hill.
12.Sugiyama, A and K.Hashimoto.1998.Effects of gastrointestinal prokinetic agents, TKS159 and cisapride, on the in situ canine heart assessed by cardiohemodynamic and electrophysiological monitoring. Toxicol Appl Pharmacol:261-9.
13.Trevor,J.,B.G Katzung and B.Susan, B.2007. Examination and Board Review, 1 ed.PP.359-472. Katzung & Trevor's Pharmacology McGraw-Hill Professional.
14.Wong, W.,H.N. Pavlou., U.M, Birgersdotter., D.E, Hilleman., S.M, Mohiuddin and D.M Roden.1992.Pharmacology of the class III antiarrhythmic agent sematilide in patients with arrhythmia. Am J Cardiol :206-212.
15. Yue,Y and et Al.2015.Pathogenesis of the Novel Autoimmune-Associated Long QT Syndrome. Circulation :115.
Veterinary Research & Biological Products
Volume 30, Issue 3 - Serial Number 116
September 2017
Pages 154-159

Files

History

  • Receive Date: 13 April 2016
  • Revise Date: 13 September 2016
  • Accept Date: 14 September 2016

Share

How to cite

Statistics